# Aquestive Therapeutics (AQST) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AQST
## Company Profile
- Ticker: AQST
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.76 USD
- Market cap: 493018967.67 USD
- Last updated: 2026-10-08
## Business Overview
### Oral Film Drug Delivery Company
Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions.
### Anaphylm
Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without water or swallowing.
### PharmFilm Platform
Aquestive's film technology controls drug loading, disintegration, and absorption in a compact dosage form and can be adapted across central nervous system and allergy products.
### Non-Injectable Epinephrine Strategy
Anaphylm is intended to offer portable and intuitive epinephrine administration without an autoinjector while producing clinically relevant systemic exposure.
### Global Regulatory Opportunity
Aquestive plans to use the Anaphylm clinical package for regulatory applications outside the United States, extending the program into Canada, Europe, the United Kingdom, and other markets.
## Why The Stock Is Moving

As of Oct 8, 2026, AQST closed up 3.03% at $4.76. No new same-company headline was identified in the current news window.

## Future Catalysts

- Resubmission of the Anaphylm NDA in the third quarter of 2026.
- Submission of an Anaphylm regulatory application in Canada by the end of 2026.
- Submission of an Anaphylm regulatory application in the European Union in the first quarter of 2027.

## Recent News
- 2026-09-29 11:00 EST — [Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-strengthens-board-of-directors-with-appointment-of-richar-daa1dc9c) — Source: Aquestive Therapeutics
- 2026-09-17 11:00 EST — [Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-resubmission-of-new-drug-application-to-fda-for-081e4d6c) — Source: Aquestive Therapeutics
- 2026-09-01 11:00 EST — [Aquestive Therapeutics to Participate in Upcoming September Investor Conferences](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-participate-in-upcoming-september-investor-conferences-7f9f1979) — Source: Aquestive Therapeutics
- 2026-08-11 20:01 EST — [Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-reports-second-quarter-2026-financial-results-and-provide-de109b2c) — Source: Aquestive Therapeutics
- 2026-08-10 11:00 EST — [Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-positive-topline-human-factors-and-pharmacokine-0e570e07) — Source: Aquestive Therapeutics